Welcome to our dedicated page for Ocular Therapeut SEC filings (Ticker: OCUL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ocular Therapeutix, Inc. (NASDAQ: OCUL) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including 8-K current reports and other documents filed with the U.S. Securities and Exchange Commission. These filings give detailed insight into Ocular Therapeutix’s clinical programs, financing activities, and key corporate events as it advances ophthalmic therapies based on its ELUTYX bioresorbable hydrogel technology.
Recent 8-K filings describe the structure and status of the AXPAXLI (OTX-TKI) registrational trials in wet age-related macular degeneration (wet AMD), including the SOL-1 and SOL-R Phase 3 studies, as well as plans for the SOL-X long-term extension trial. They also outline the design of the HELIOS-2 and HELIOS-3 Phase 3 trials in non-proliferative diabetic retinopathy (NPDR), the use of a novel ordinal diabetic retinopathy severity score (DRSS) endpoint, and Special Protocol Assessment (SPA) agreements with the FDA.
Other filings cover capital markets transactions, such as the September 30, 2025 underwriting agreement for a large common stock offering, expected net proceeds, and the company’s view of its cash runway into future years. Additional 8-Ks furnish quarterly financial results press releases, describe inducement equity awards under Nasdaq Listing Rule 5635(c)(4), and discuss notices of allowance from the U.S. Patent and Trademark Office related to AXPAXLI methods of use.
On Stock Titan, these SEC filings are updated in near real time from EDGAR and can be paired with AI-powered summaries that explain the key points of lengthy documents like 8-Ks or registration statements in plain language. Users can quickly see how Ocular Therapeutix reports on trial designs, primary endpoints, regulatory interactions, cash resources, and potential patent protection. For investors tracking OCUL, this page is a central place to review official disclosures about clinical progress, financing arrangements, and other material events that may influence the company’s ophthalmology-focused pipeline and commercial product DEXTENZA.
Oculus Therapeutics (OCUL) reported proposed sales of common stock via a Form 144 notice tied to restricted shares vesting under a registered plan on 02/22/2026.
The filing names Pravin Dugel and lists prior sales of 124,882 shares on 02/12/2026 for $1,128,583.61 and 19,530 shares on 11/24/2025 for $235,082.61.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a notice regarding the proposed sale of 3,057 common shares tied to restricted stock vesting under a registered plan, dated 02/22/2026. The filing lists that the sale method is by the Issuer.
The excerpt also shows a prior sale by Jeffrey S. Heier of 3,469 common shares on 11/24/2025, with a numeric value 41,771.96 recorded alongside that transaction.
OCUL notice of a proposed sale of 1,759 common shares tied to restricted stock vesting under a registered plan on 02/22/2026.
The filing also records prior sales by Sanjay Nayak of 10,348 shares on 02/12/2026 and 1,878 shares on 11/24/2025.
Nadia K. Waheed submitted a Form 144 reporting a proposed sale of 3,510 shares of common stock tied to restricted stock vesting under a registered plan, dated 02/11/2026. The filing also shows 7,863 shares were sold on 02/12/2026.
Ocular Therapeutix Chief Operating Officer Donald Notman reported an automatic open-market sale of 11,446 shares of common stock at a weighted average price of $9.04 per share on February 12, 2026. The sale was executed under a durable automatic sale instruction to satisfy tax withholding obligations tied to restricted stock units that vested on February 11, 2026, and was not a discretionary trade. Following this transaction, Notman directly owns 366,356 shares of Ocular Therapeutix common stock.
Ocular Therapeutix Chief Strategy Officer Sanjay Nayak executed an automatic sale of 10,348 shares of common stock on February 12, 2026 at a weighted average price of $9.04 per share. The transaction was carried out under a durable automatic sale instruction to cover tax withholding obligations tied to restricted stock units that vested on February 11, 2026, and was not a discretionary trade. After this sell-to-cover transaction, Nayak directly held 332,412 shares of Ocular Therapeutix common stock.
Ocular Therapeutix director and officer Pravin Dugel reported an open‑market sale of 124,882 common shares at a weighted average price of $9.04 per share. The transaction was made under a durable automatic sale instruction adopted on February 21, 2024 to satisfy tax withholding obligations from restricted stock units vesting on February 11, 2026.
After this sale, Dugel holds 3,033,078 common shares directly.
Ocular Therapeutix Chief Medical Officer Nadia Waheed reported an open-market sale of 7,863 shares of common stock on February 12, 2026 at a weighted average price of $9.04 per share. The sale was made under a durable automatic sale instruction to cover tax withholding on vested restricted stock units and was not a discretionary trade. After this transaction, she directly holds 318,417 shares.
Ocular Therapeutix Inc. is the subject of an updated ownership report from Venrock-affiliated investment entities. The Schedule 13G/A (Amendment No. 3) shows the group beneficially owning 6,862,972 shares of common stock, representing 3.2% of the company as of December 31, 2025.
This stake is held across Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, and Venrock Healthcare Capital Partners EG, L.P., with management entities and individuals Nimish Shah and Bong Y. Koh sharing voting and dispositive power. The filing notes the securities are not held for the purpose of changing or influencing control of Ocular Therapeutix.
Ocular Therapeutix shareholder Donald D Notman Jr. filed a notice of proposed sale under Rule 144 covering 11,446 shares of common stock. These shares came from restricted stock that vested under a registered plan on 02/11/2026 and are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ.
The filing notes that 217,691,779 common shares were outstanding. Over the prior three months, the same seller disposed of 6,035 shares on 02/04/2026 for gross proceeds of 51,540.71 and 5,455 shares on 02/02/2026 for 49,872.88. The signer represents having no undisclosed material adverse information about Ocular Therapeutix.